Showing results (2921-2930 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|March 4, 2005
Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trialTa-Chung Chao, Zyting Chu, Ling-Ming Tseng, et al.Investigational New Drugs|March 4, 2005
Phase II trial of fenretinide in advanced renal carcinomaUlka Vaishampayan, Lance K Heilbrun, Ralph E Parchment, et al.Investigational New Drugs|May 4, 2004
Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: a preclinical studyDanila Coradini, Cinzia Pellizzaro, Gabriella Abolafio, et al.Investigational New Drugs|May 4, 2004
Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agentGary P Wilkinson, James P Taylor, Steve Shnyder, et al.Investigational New Drugs|May 4, 2004
Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinomaThomas E Hutson, Ram Ganapathi, Paul Elson, et al.Investigational New Drugs|May 4, 2004
Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancerEardie A Curry, Daryl J Murry, Christy Yoder, et al.Investigational New Drugs|May 4, 2004
Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancerPaulo M Hoff, Everardo D Saad, Richard Pazdur, et al.Investigational New Drugs|May 4, 2004
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanomaSusan Burdette-Radoux, Richard G Tozer, Reinhard C Lohmann, et al.Investigational New Drugs|May 4, 2004
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortiumHedy L Kindler, Anjali Avadhani, Kurombi Wade-Oliver, et al.Investigational New Drugs|November 18, 2021
Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancerHisanaga Nomura, Daiki Tsuji, Shohei Ueno, et al.Pageof 372